Please login to the form below

Not currently logged in
Email:
Password:

Pfizer completes $164m cash tender offer for Coley

Pfizer completes a cash tender offer to purchase all of the outstanding shares of US-based biopharmaceutical company, Coley Pharmaceutical

On 1 January 2008, Pfizer said it had completed a cash tender offer to purchase all of the outstanding shares of US-based biopharmaceutical company, Coley Pharmaceutical.

Pfizer said the $164m tender offer for Coley expired at midnight on 28 December 2007. The offer was not extended.

Pfizer said it has purchased close to 25 million shares of Coley common stock. The shares represent approximately 92.2 per cent of Coley's outstanding common stock, according to a Pfizer statement.

The world's largest pharmaceutical company plans to complete the merger in the coming days. Remaining Coley shareholders will receive the same $8.00 cash price per share paid in the tender offer, the release added.

Following the merger, Coley will become an indirect wholly owned subsidiary of Pfizer.

2nd January 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....

Infographics